Sandra Calvin
SVP, CHIEF ACCOUNTING OFFICER · 3 filings · Latest: Sep 15, 2026
Travere Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
TVTX | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale | $62.33 | 5,375 | $335.0K | 42,353 | |
TVTX | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option Exercise | $24.19 | 5,375 | $130.0K | 47,728 | |
TVTX | SANDRA CALVIN | — | Sep 15, 2026 | Proposed Sale | $65.79 | 5,375 | $353.6K | — | |
TVTX | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Apr 14, 2026 | Sale | $41.07 | 21,977 | $902.6K | 42,353 | |
TVTX | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Apr 14, 2026 | Option Exercise | $16.05 | 15,250 | $244.8K | 64,330 | |
TVTX | SANDRA CALVIN | — | Apr 14, 2026 | Proposed Sale | $41.07 | 21,977 | $902.6K | — | |
TVTX | Sandra Calvin | — | Feb 3, 2026 | Proposed Sale | $32.12 | 4,333 | $139.2K | — | |
TVTX | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Feb 3, 2026 | Sale | $32.12 | 4,333 | $139.2K | 49,080 | |
TVTX | SANDRA CALVIN | — | Dec 24, 2025 | Proposed Sale | $40.00 | 7,402 | $296.1K | — | |
TVTX | SANDRA CALVIN | — | Dec 15, 2025 | Proposed Sale | $36.00 | 2,910 | $104.8K | — | |
TVTX | SANDRA CALVIN | — | Nov 4, 2025 | Proposed Sale | $36.00 | 67,115 | $2.4M | — | |
TVTX | SANDRA CALVIN | — | Feb 11, 2025 | Proposed Sale | $25.00 | 54,244 | $1.4M | — | |
TVTX | Sandra Calvin | — | Feb 3, 2025 | Proposed Sale | $20.12 | 3,348 | $67.4K | — | |
TVTX | SANDRA CALVIN | — | Dec 26, 2024 | Proposed Sale | $17.22 | 15,000 | $258.3K | — | |
TVTX | Calvin Sandra | — | Nov 25, 2024 | Proposed Sale | $18.30 | 12,090 | $221.3K | — | |
TVTX | Calvin Sandra | — | Sep 11, 2024 | Proposed Sale | $14.80 | 15,000 | $222.0K | — |